| Expression pattern: |
DN |
| Associated gene: |
CELF2, PTEN, PCNA, MMP2 |
| Associated microRNA: |
miR-134-5p |
| Biological function: |
circPTK2 functions as a tumor suppressor in gastric cancer; overexpression suppresses proliferation, colony formation, DNA synthesis, cell invasion, xenograft tumor growth and lung metastasis, while knockdown promotes proliferation and invasion. |
| Molecular mechanism: |
circPTK2 sponges miR-134-5p to activate CELF2/PTEN signaling and downregulate PCNA and MMP2 expression. |
| Biological pathway or process: |
ceRNA regulation (other); proliferation (inhibits); invasion (inhibits); metastasis (inhibits); other pathway/process (promotes) |
| Detected method: |
Q
H
M
|
| Validation methods: |
Microarray; RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; FISH / smFISH; Clinical Sample Validation; circRIP; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; Transwell Assay; Western Blot; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
Low circPTK2 expression was related to poor survival in GC patients; patients with low circPTK2 expression had shorter OS than those with high circPTK2 expression, although circPTK2 was not an independent prognostic factor. |
| Description: |
hsa_circ_0006421/circPTK2 is down-regulated in gastric cancer and acts as a tumor suppressor. It sponges miR-134-5p in the cytoplasm, activating CELF2/PTEN signaling and reducing PCNA and MMP2 expression, thereby inhibiting GC cell proliferation, invasion, tumor growth and lung metastasis. Low circPTK2 expression is associated with shorter overall survival in GC patients. |
| Confidence score: |
0.8658 |